Cannabidiol not checked

Jazz Pharmaceuticals · JZP926 · GWP42003

FollowEvery change as it happens, and a Monday email
Stage
in the US · approved in the EU
Next date
Phase 4 trial completes
Trials
17 active
51 in total · 25 in the EU
Targets
GPR55 · 5-HT1A · CB2 · CB1
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Starting dose of CBD-OS will be administered as per the approved local product label”In the company’s words, NCT07233239 on ClinicalTrials.gov
Tested for
Lennox Gastaut Syndrome, Dravet Syndrome, Tuberous Sclerosis Complex, Lennox-Gastaut Syndrome, Developmental and Epileptic Encephalopathy (DEE), Juvenile Myoclonic Epilepsy, Focal Seizures
Main trialPhase 4
“This study will monitor for potential chronic liver injury and liver fibrosis, in participants treated with cannabidiol oral solution.”In the company’s words, NCT05044819 on ClinicalTrials.gov
Other names
JZP926 · CBD-OS · Epidiolex · Epidyolex · GWP42003 · CBD · GWP42003-P · JZP926-OS

Other drugs for Lennox Gastaut Syndrome

All 5 drugs for Lennox Gastaut Syndrome

Coming up5

Changes1

Last 90 days

Trials51

TrialPhaseCompletesWhat it tests
Phase 4Active, not recruiting 1 Aug 2027 Assessment of Potential for Chronic Liver Injury in Participants Treated With Epidiolex (Cannabidiol) Oral Solution
Phase 4Not yet recruiting 28 Dec 2028 A Study to Investigate the Effect of Gradual Titration to Optimize Cannabidiol Treatment in Adults With LGS
Phase 3Recruiting 4 Sep 2029 A Study to Evaluate the Safety and Efficacy of CBD-OS in Participants With DEE
Phase 2/3Recruiting 1 Aug 2028 A Study to Evaluate the Safety and Efficacy of JZP926 Capsule for the Treatment of Juvenile Myoclonic Epilepsy
Phase 1Recruiting 29 Nov 2027 A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Phase 4Withdrawn Dec 2021 Investigation of Cognitive Outcomes With Cannabidiol Oral Solution
Phase 4Completed 6 Apr 2026 A Study to Investigate Behavioral and Other Co-Occurring Outcomes With Epidiolex as Add-On Therapy in Participants Aged 1 to 65 Years of Age With Tuberous Sclerosis Complex
Phase 3Completed 26 Nov 2015 Antiepileptic Efficacy Study of GWP42003-P in Children and Young Adults With Dravet Syndrome (GWPCARE1)
Phase 3Completed 18 Mar 2016 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P; CBD) as Adjunctive Treatment for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Phase 3Completed 19 May 2016 Efficacy and Safety of GWP42003-P for Seizures Associated With Lennox-Gastaut Syndrome in Children and Adults
Phase 3Completed 9 Apr 2018 GWPCARE2 A Study to Investigate the Efficacy and Safety of Cannabidiol (GWP42003-P) in Children and Young Adults With Dravet Syndrome
Phase 3Completed 7 May 2018 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms (GWPCARE7)
Phase 3Completed 22 Jan 2019 A Randomized Controlled Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Phase 3Completed 13 Jun 2019 Phase 3 Trial of Cannabidiol (CBD; GWP42003-P) for Infantile Spasms: Open-label Extension Phase (GWPCARE7)
Phase 3Terminated 21 Jan 2021 Efficacy and Safety of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Phase 3Terminated 9 Jun 2021 A Long-term Safety Study of Cannabidiol Oral Solution (GWP42003-P, CBD-OS) in Patients With Rett Syndrome
Phase 3Completed 11 Jun 2021 An Open-label Extension Trial of Cannabidiol (GWP42003-P, CBD) for Seizures in Tuberous Sclerosis Complex (GWPCARE6)
Phase 3Terminated 28 Sep 2023 Efficacy and Safety of GWP42003-P Oral Solution in Children With Epilepsy With Myoclonic-atonic Seizures
Phase 3Terminated 28 Jan 2025 Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures
Phase 2Completed May 2012 GWMD1092 - GWP42003 : GWP42004 Together Plus Alone in Type II Diabetes
Phase 2Completed 8 Jan 2015 A Study of GWP42003 as Adjunctive Therapy in the First Line Treatment of Schizophrenia or Related Psychotic Disorder
Phase 2Completed 9 Mar 2015 A Dose-ranging Pharmacokinetics and Safety Study of GWP42003-P in Children With Dravet Syndrome (GWPCARE1)
Phase 2Completed 21 Jul 2016 A Randomized Controlled Trial to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Phase 2Completed 7 Jun 2017 An Open-label Extension Study to Investigate Possible Drug-drug Interactions Between Clobazam and Cannabidiol
Phase 2Completed 11 Sep 2018 A Study of Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
Phase 2Completed 27 May 2019 An Open-label Extension Trial to Investigate Possible Drug-drug Interactions Between Stiripentol or Valproate and Cannabidiol in Patients With Epilepsy
Phase 2Terminated 16 Mar 2022 Trial to Investigate the Safety and Efficacy of GWP42003-P Versus Placebo as Adjunctive Therapy in Participants With Schizophrenia Experiencing Inadequate Response to Ongoing Antipsychotic Treatment
Phase 2Completed 21 Dec 2023 Trial to Investigate the Safety and Efficacy of Cannabidiol Oral Solution (GWP42003-P; CBD-OS) in Children and Adolescents With Autism Spectrum Disorder
Phase 2Authorised not given Open-label pilot study to assess the efficacy and safety of Cannabidiol oral solution as an adjunctive treatment for children and young adults with rare disease-associated severe epilepsy
Phase 2Not authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 2Not authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 2Authorised not given Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
Phase 3Not authorised not given Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
Phase 3Authorised not given Randomized, double-blind, Placebo-controlled, 2x2 cross over study assessing the efficacy and safety of cANnabidiol oral solution for joint pain of adjuvant enDOcrine theRApy in patients with early breast cancer (PANDORA)
Phase 2Ended not given Explorative, randomized, double-blind, placebo-controlled, 3-way cross-over study to assess the effects of oral cannabidiol 30 and 700 mg in healthy male subjects on CNS and cortical excitability using the NeuroCart test battery and TMS.
Phase 2Authorised not given Efficacy and safety of cannabidiol for pain relief of patients with end-stage metastatic castration resistant prostate cancer - a randomised double-blinded placebo-controlled phase II trial (ProCan)
Phase 2Authorised not given A phase 2a study on the anti-tumoral effect of cannabis oil (THC 10% / CBD 5%) in patients with untreatable advanced hepatocellular carcinoma - the CanHep study
Phase 2Ended not given Cannabidiol as an Add-on Treatment to substance abuse in juvenile patients with PSYchosis: a double-blind randomized placebo-controlled study.
Phase 2Ended not given A Pilot / Phase 2 Clinical Trial of GSL-01-001 Administered Orally for 12 Weeks Preceded by a 2 Week Screening Period in Patients Presenting with Symptoms Associated with Irritable Bowel Syndrome with code GSL-01-001
Phase 2Ended not given BOOSTCAMP - Boosting the endocannabinoid system before the treatment of anxiety symptoms
Phase 2Halted not given CBD-ESPRIT - Enhancing recovery in early schizophrenia – a multi-center, two-arm, double-blind, randomized clinical trial investigating cannabidiol vs. placebo as an add-on to an individualized antipsychotic treatment
Phase 2/3Ended not given Cannabidiol for treatment of non-affective psychosis and cannabis use
Phase 2Ended not given Cannabidiol for reducing drinking in alcohol use disorder and modifying the effects of alcohol on the brain and the liver: a phase 2 clinical trial.- The CARAMEL Study
Phase 2Authorised not given ICONICplus - Randomized, double-blind, placebo-controlled trial to investigate the Effects of Cannabidiol plus Naltrexone on Cue-Induced Alcohol Craving in Alcohol Dependence
Phase 2Ended not given The CanISleepinMS Study: Effect of cannabidiol (CBD) on sleep quality in patients with multiple sclerosis, a series of 15 randomised, placebo-controlled N-of-1 trials
Phase 2Authorised not given CBD-OH - Cannabidiol as an add-on treatment during inpatient alcohol cessation in patients with severe alcohol use disorder: a Phase II trial
Phase 2Authorised not given The effect of CBD on sleep quality following late evening exercise
Phase 2Authorised not given PANACEA : Effect of PrehAbilitation by NutritionAl supplementation with Cannabidiol on skeletal muscle mass and mitochondrial function in hEad and neck cAncer : a proof of concept controlled randomized trial
Phase 3Authorised not given Cannabidiol (Epidyolex) for behavioural problems in patients with Tuberous Sclerosis Complex, Sanfilippo and Fragile X syndrome: an N-of-1 series
Phase 2Authorised not given CBD-SIB - Efficacy of cannabidiol in the management of Self-Injurious Behavior in children and adolescents with severe neurodevelopmental disorders
Phase 3Authorised not given AugmENtation witH cAnnabidiol iN first episode psyChosis: a doublE blind randomised controlled trial (STEP-ENHANCE Trial)
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Cannabidiol

Following is part of Solo: you see every change to Cannabidiol the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in